Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 12, 2026
Enovis Corp (ENOV)
A forensic read on Enovis Corp built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-1.5
Distress distance
Clean
Earnings quality
5
Forensic signals
-1.4
P / E (ttm)
-79.5%
ROE
$1.4B
Market cap
0.00%
Dividend yield
6.7%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Enovis Corp earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads -1.5, placing it in the Distress zone. 5 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-27.5%
FY2025
Return on invested capital.Return on invested capital is -27.5% in the latest fiscal year and slipping from -1% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+1.8%/yr
FY2022–FY2025
Share-count dilution.Diluted share count changed +6% over the last 3 years to FY2025 (+1.8%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~1.8% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~5%.
69d DSO
FY2024→FY2025
Receivables vs revenue.Days sales outstanding moved from 60 to 69 days FY2024→FY2025 (receivables +9% vs revenue +7%). Receivables are creeping up relative to sales. Across FY2021–FY2025 the day count ran 99 → 61 → 60 → 60 → 69 days, so the latest reading sits on top of a record that was flat or falling before it — one year's move, not a direction the business has been travelling in.
229d
FY2024→FY2025
Inventory days.Days inventory outstanding moved from 200 to 229 FY2024→FY2025 (against cost of goods sold; inventory +7% vs -3% in cost of sales). Inventory is building a little faster than sales — watch for markdowns.
$1.7B
FY2024–FY2025
Goodwill impairments.
Key fundamentals
Latest Revenue$2.25B
Revenue Growth YoY+6.7%
Revenue CAGR (3yr)+12.9%
Net Margin-52.7%
Free Cash Flow$19.9M
Return on Equity-79.5%
Debt / Equity0.87x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Enovis Corp's actual 10-K/10-Q/8-K filings?
Data from SEC EDGAR public filings · metrics as of Aug 12, 2026. Forensic signals flag probability, not certainty.
Took $1.7B of goodwill writedowns across 2 years (FY2024 ($645M), FY2025 ($1.0B)). Writedowns mean past acquisitions underperformed what was paid for them.